secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0000950170-25-105485
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3
------------------------------------------------------------------------

- Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.
- Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.
- Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.
- Raised $4M gross proceeds from public offering in May 2025.
- Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/0000950170-25-105485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-20250808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer